AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oramed Pharmaceuticals Inc. Director's Dealing 2021

Feb 8, 2021

6965_dirs_2021-02-08_cf4764aa-af62-40d3-a110-31bf9ab026a1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2021-02-03

Reporting Person: Kidron Miriam (Director, Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-03	Stock Option (right to buy)	$10.40	A	100000	Acquired	2031-02-03	Common Stock (100000)	Direct

Footnotes

F1: The Stock Option will vest in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.